10x Genomics (TXG) Misses Q2 EPS by 13c; Offers FY23 Guidance

10x Genomics (NASDAQ: TXG) reported Q2 EPS of ($0.53), $0.13 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $146.8 million versus the consensus estimate of $139.97 million.

GUIDANCE:

10x Genomics sees FY2023 revenue of $600-620 million, versus the consensus of $601.7 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Mannatech (MTEX) Tops Q2 EPS by 53c
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c